Literature DB >> 630676

Antiarrhythmic effects of aspirin during nonthrombotic coronary occlusion.

C B Moschos, B Haider, C De La Cruz, M M Lyons, T J Regan.   

Abstract

To study the action of aspirin upon the myocardium per se, independent of thrombosis, coronary occlusion with a balloon catheter was induced in 53 anesthetized dogs divided into two groups. One group (N = 20) was treated daily with aspirin (600 mg/dog) for seven days and another (N = 33) was untreated. Left ventricular hemodynamics and precordial ECG mapping were used to assess the influence of myocardial ischemia over a four hour period. There were no significant differences in left ventricular function or extent of injury as judged by ECG mapping between the two groups. However, there was a significant decrease in the incidence of ventricular fibrillation in the treated dogs (5% vs 39%). Serial plasma samples for free fatty acid determination showed a significant rise in the untreated group. Aspirin blocked the FFA increment in the treated animals. Tissue samples from the ischemic area of left ventricle exhibited a significant reduction of the sodium and water increments, as well as a lesser potassium loss in the treated animals compared to the controls and may have been the basis for the lower incidence of arrhythmias. Since infusion of 51Cr labelled platelets showed no myocardial accumulation of platelets in either group, microthrombi did not appear to contribute to the observed differences.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 630676     DOI: 10.1161/01.cir.57.4.681

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Aspirin in the prevention of myocardial infarction. Current status.

Authors:  P C Elwood
Journal:  Drugs       Date:  1984-07       Impact factor: 9.546

2.  Thrombosis: its role and prevention in cardiovascular events--Part I. Concepts of thrombogenesis and its prevention.

Authors:  L A Harker
Journal:  West J Med       Date:  1981-03

Review 3.  Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events.

Authors:  Joonseok Kim; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

4.  Lack of direct antiarrhythmic electrophysiological effects of salicylate on isolated guinea-pig myocardium.

Authors:  H Brasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-08       Impact factor: 3.000

5.  Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction.

Authors:  R M Norris; H D White; D B Cross; K S Woo; A H Maslowski; M P Caruana; H H Hart; B Williams
Journal:  Br Heart J       Date:  1993-06

6.  A selective concentration-dependent dysrhythmogenic and antidysrhythmic action of prostaglandins E2, F2 alpha and I2 (prostacyclin) on isolated rat hearts.

Authors:  M Karmazyn; N S Dhalla
Journal:  Experientia       Date:  1980-08-15

7.  Aspirin inhibits the early myocardial release of thromboxane B2 and ventricular ectopic activity following acute coronary artery occlusion in dogs.

Authors:  S J Coker; I M Ledingham; J R Parratt; I J Zeitlin
Journal:  Br J Pharmacol       Date:  1981-04       Impact factor: 8.739

Review 8.  Coronary artery vasospasm: the likely immediated cause of acute myocardial infarction.

Authors:  H R Hellstrom
Journal:  Br Heart J       Date:  1979-04

9.  Effects of aspirin and prostacyclin on arrhythmias resulting from coronary artery ligation and on infarct size.

Authors:  K M Johnston; B A MacLeod; M J Walker
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

10.  Platelet depletion in experimental myocardial infarction.

Authors:  S R Jolly; W A Schumacher; S L Kunkel; G D Abrams; J Liddicoat; B R Lucchesi
Journal:  Basic Res Cardiol       Date:  1985 May-Jun       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.